Yingbin West Road, North District, Hantai Economic Development Zone, Hanzhong city, Shaanxi Province
No.6 Gaoxin Avenue, Chuangzhi Industrial Park, Hanzhong Economic and Technological Development Zone, Shaanxi Province
Scan the code to pay attention to the public number
News
Good News | Hanwang Pharmaceutical’s Qiangli Dingxuan product has been successfully included in the 2026 National Essential Medicines List.
Release time ：
2026-07-09 00:00
On July 9, the National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration jointly announced… 2026 Edition of the National Essential Medicines List , the total number of drugs listed in the new edition has been expanded from 685 to 794. The product of Shaanxi Hanwang Pharmaceutical Co., Ltd. has been successfully selected—Qiangli Dingxuan Tablets (Capsules). , marking the product’s official inclusion in the national core drug system—essential for clinical use, prioritized at the primary care level, and widely accessible to the entire population.
This successful inclusion in the new edition of the National Essential Medicines List reflects the recognition by the national regulatory authorities of Qiangli Dingxuan Tablets. Outstanding clinical value, proven efficacy, consistent quality, and safety and cost-effectiveness. comprehensive and authoritative certification. Previously, the product had already been successfully included in The Fourth National Centralized Procurement Catalogue of Traditional Chinese Medicinal Products With the dual support of national-level policies, the product’s core market competitiveness has been further strengthened, marking a major milestone in the company’s history.
As originating from a classic renowned formula, A nationally exclusive variety, a nationally protected traditional Chinese medicine product, and a product covered by a national invention patent. Qiangli Dingxuan Tablets are meticulously formulated using time-honored traditional methods, offering triple benefits—lowering blood pressure, reducing lipids, and alleviating dizziness—and precisely addressing common clinical conditions such as hypertension, atherosclerosis, hyperlipidemia, and associated symptoms like headache, dizziness, vertigo, tinnitus, and insomnia. Backed by more than four decades of clinical experience, the product has earned a strong reputation for its safe, reliable efficacy and positive patient feedback, providing long-term health support to millions of patients with chronic diseases.
In recent years, the evidence‑based support for Qiangli Dingxuan Tablets has continued to strengthen, and they have been recommended for use in numerous clinical practice guidelines and medical textbooks. To date, Qiangli Dingxuan Tablets have been included in a total of 14 guidelines, consensus statements, and medical textbooks. It is recommended for the clinical management of vertigo caused by a variety of common conditions—including chronic cerebral ischemia, benign paroxysmal positional vertigo (BPPV), Meniere’s disease, cervical spondylosis, cerebral insufficiency, hypertension, hyperlipidemia, persistent postural‑perceptual dizziness (PPPD), and anxiety or depression—providing guideline‑based evidence to inform clinical practice.
Standing at a new starting point, we embark on a new journey. Looking ahead, Hanwang Pharmaceutical will seize this opportunity to remain true to its original aspirations and mission in the pharmaceutical field, deepen its commitment to the inheritance and innovation of traditional Chinese medicine, uphold the highest standards of drug quality and safety, and continuously refine its portfolio of high‑quality proprietary Chinese medicines. Leveraging the dual policy advantages of essential medicines and centralized procurement, the company will continue to optimize its product offerings and service system, safeguarding public health with premium TCM products and vigorously driving the high‑quality development of the TCM industry.
Previous page
Address
Yingbin West Road, North District, Hantai Economic Development Zone, Hanzhong city, Shaanxi Province
No.6 Gaoxin Avenue, Chuangzhi Industrial Park, Hanzhong Economic and Technological Development Zone, Shaanxi Province
Follow public account
Shaanxi Hanwang Pharmaceutical Co., LTD Powered by www.300.cn SEO Internet Drug Information Service qualification certificate (Shaanxi)- Non-operational-2021-0172
Email
Focus on
The public
Follow the official account for more inspiration
- Top